Overview

Phase 2 Bunionectomy HTX-011 Administration Study

Status:
Completed
Trial end date:
2019-03-11
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open-label, multi-cohort study to evaluate the analgesic efficacy, safety, and pharmacokinetics (PK) of a single, individualized dose of HTX-011 administered into the surgical site as a monotherapy or with other medications to enhance analgesia in subjects undergoing unilateral simple bunionectomy.
Phase:
Phase 2
Details
Lead Sponsor:
Heron Therapeutics
Treatments:
Aprepitant